Thomas Reiberger

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Rajiv Jalan

UNITED KINGDOM

View details

Michael Schwarz

Medical University of Vienna

AUSTRIA

View details

Francesco Violi

Full Professor of Internal Medicine

Università degli Studi di Roma La Sapienza

ITALY

View details

Tobias Meischl

Medical University of Vienna

AUSTRIA

View details

Peter Ferenci

Medical University of Vienna

AUSTRIA

View details

Georg Semmler

Medical University of Vienna

AUSTRIA

View details

Lukas Hartl

Medical University of Vienna

AUSTRIA

View details

Lorenz Balcar

Medical University of Vienna

AUSTRIA

View details

Vanessa Stadlbauer

AUSTRIA

View details

Karen Louise Thomsen

DENMARK

View details

Mohamed bouattour

Head of Unit

FRANCE

View details

Juan Carbonell-Asins

Head of Unit

Instituto de Investigación Sanitaria La Fe

SPAIN

View details

Jaime Bosch

Emeritus Professor of Medicine

University of Barcelona

SPAIN

View details

Heinz Zoller

AUSTRIA

View details

Michael Trauner

Professor of Medicine and Chair of Gastroenterology and Hepatology

Medical University of Vienna

AUSTRIA

View details

Giovanna Ferraioli

Università degli Studi di Pavia Dipartimento di Scienze Clinico-Chirurgiche Diagnostiche e Pediatriche

ITALY

View details

Frank Tacke

GERMANY

View details

Benedikt Simbrunner

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Reiberger

Research Interests

Explore related searches

Contact this professor

Articles (20)

Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma

Endoscopic diagnosis and treatment for portal hypertension: not yet ready for clinical practice!

Hepatic immune regulation and sex disparities

Reticulated platelets in cirrhosis – Just a surrogate for thrombocytopenia?

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply

Portal hypertension and its prognostic implications in patients with Wilson's disease

Does encephalopathy with early onset after TIPS impact on mortality?

Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply

Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply

Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

Reply to: Ammonia predicts clinical outcomes in cirrhosis – but there are caveats to consider.

Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?

Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes

Platelet Function Decreases with Increasing Severity of Liver Cirrhosis and Portal Hypertension—A Prospective Study

Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis

Reply to: “3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta”

Two-dimensional shear wave elastography (ElastQ) accurately rules out liver fibrosis and rules in advanced chronic liver disease across liver disease etiologies: a prospective multicenter study

Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension

The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

Collaborators (18)

Rajiv Jalan

Michael Schwarz

Francesco Violi

Tobias Meischl

Peter Ferenci

Georg Semmler

Lukas Hartl

Lorenz Balcar

Vanessa Stadlbauer

Karen Louise Thomsen

Mohamed bouattour

Juan Carbonell-Asins

Jaime Bosch

Heinz Zoller

Michael Trauner

Giovanna Ferraioli

Frank Tacke

Benedikt Simbrunner

Make your next move.